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Abstract
Background: In a randomised controlled trial, contamination is defined as the receipt of active intervention
amongst participants in the control arm. This review assessed the processes leading to contamination, its typical
quantity, methods used to mitigate it, and impact of use of cluster randomisation to prevent it on study findings in
trials of complex interventions in mental health.
Methods: This is a scoping review of trial design approaches and methods of study conduct to address contamination.
Studies included were randomised controlled trials of complex interventions in mental health that described the process
leading to, amount of, or solution used to counter contamination. The Medline, Embase, and PsycInfo databases were
searched for trials published between 2000 and 2015. Risk of bias was assessed using the Jadad score and domains
recommended by Cochrane plus some relevant to cluster randomised trials.
Results: Two hundred and thirty-four articles were included in the review. The main processes that led to contamination
were health professionals delivering both active and comparator treatments and communication among clinicians and
participants from the different trial arms. Twenty-three trials (10%) measured binary treatment receipt in the control arm
with median 13% of participants found to be contaminated (IQR 5–33%). The most common design approach for dealing
with contamination was the use of cluster randomisation (n = 93). In addition, many researchers used simple trial conduct
methods to minimise contamination due to suspected contamination processes, such as organising for each clinician to
provide only one treatment and separating trial arms spatially or temporally. There was little evidence for a relationship
between cluster randomisation to avoid contamination and size of treatment effect estimate.
Conclusion: There was some evidence of modest levels of treatment contamination with a large range, although a
minority of studies reported the amount of contamination. A limitation was that many trials described the problem in
little detail. Overall there is a need for greater measurement and reporting of treatment receipt in the control arm of trials.
Researchers should be aware of trial conduct methods that can be used to minimise contamination without resorting to
cluster randomisation.
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Background
Treatment contamination is defined as the receipt of
active intervention amongst participants in the control
arm of a randomised controlled trial (RCT) [1]. It is
thought to be particularly prevalent in RCTs of complex
interventions in mental health. Psychological therapies
are complex interventions that comprise several inter-
acting constituent parts [2]. Such intervention compo-
nents are often transportable and difficult to confine,
meaning that their receipt by participants within the
control arm is possible. The effect of contamination is to
make the control arm more similar to the active inter-
vention arm, i.e. to dilute the treatment contrast. This is
a concern to researchers because the contrast between
the randomised groups (intention-to-treat estimator) will
be biased for the effect of treatment receipt (efficacy).
The processes leading to contamination in trials of
complex interventions in mental health have never been
reviewed comprehensively and the literature is unclear
about their relative frequencies. This is necessary in
order to plan what steps should be taken to address the
problem. In mental health the typical quantity of con-
tamination, some of the methods that researchers take
to minimise or prevent it, and the extent to which it im-
pacts on study findings are either little known or poorly
formalised within the literature. Here we undertake a
comprehensive scoping review that addresses these
points. This type of review is defined as a map of litera-
ture within a research area that identifies key concepts;
gaps in research; and types and sources of evidence, in
order to inform practice, policymaking and research [3].
Previous reviews have assessed the extent of contamin-
ation in certain areas of medicine. For example, a litera-
ture review of 235 RCTs of guideline dissemination and
implementation strategies for healthcare professionals
identified eight trials that quantified contamination [1].
The review assessed the proportion of participants in
the control arm who were considered to have received
treatment and found a median of 24% of participants to
be contaminated (range 0–65%). In oncology, a large
breast cancer screening trial (n = 9780) found that 22%
of those in control arm received a mammogram outside
the trial compared to 5% of the intervention group doing
likewise [4]. A review of cancer trials using Zelen’s de-
sign, where patients consent to their randomly allocated
treatment before being asked for consent to participate
in the study, found 11 trials that reported the number of
patients who switched treatments [5, 6]. The average
was 18% (range 10–36%). However, this figure did not
represent solely contamination as many of the studies in
the review described switches from active to comparator
treatments or provided an overall summary of switches
in either direction. The scale of the problem in mental
health trials remains unclear.
In terms of steps that might be undertaken to minim-
ise the occurrence of contamination, we distinguish be-
tween statistical design methods, trial conduct solutions,
and analytical approaches. The main statistical design
method is the use of cluster randomisation, which can
prevent contamination provided that clusters are con-
structed at the level at which it takes place [7]. By ensur-
ing that all participants within a cluster receive the same
treatment, contamination of the control condition due
to participants being affected by each other’s treatment
receipt can be avoided. However, the cost of such a de-
sign is that correlation within clusters must be factored
into a power calculation and will inflate the sample size
requirement. Sample size is inflated by design factor, D.
D≔1þ I k−1ð Þ
where I is the intraclass correlation coefficient and k is
the cluster size. In addition, cluster randomised con-
trolled trials (cRCTs) often suffer from selection biases,
mainly due to treatment being known before participant
entry into trial (recruitment bias) and differential loss to
follow-up between trial arms (attrition bias) [8]. The sec-
ond type of strategy (trial conduct solutions) relates to
methods that can be used in the running of the trial to
reduce exposure of the control arm to active interven-
tion. Education of clinicians and participants against
contamination and provision of clear information about
the purposes of the trial have been suggested [1]. How-
ever, it remains an open question as to what methods re-
searchers use in practice. In terms of analytical methods
that adjust for contamination, the use of modern causal
estimation techniques has been advocated for this pur-
pose [9–11], but it is not known how widely these have
been used.
The review of educational interventions in RCTs also
assessed whether there was any link between the preven-
tion of contamination (e.g. through use of cluster ran-
domisation) and an increase in the size of treatment
effect estimates [1]. When assessing all studies in the set
there was no evidence for such a link; however, a more
homogeneous sample showed some evidence of a rela-
tionship. Other reviews have found similarly mixed re-
sults. For example, a review of 14 hip protector trials
showed large positive effects in cluster RCTs and a mix-
ture of positive and negative effects in RCTs with
individual-level randomisation with suspected contamin-
ation [12]. On the other hand, a meta-analysis of 34
RCTs of enhanced care for depression found very similar
treatment effect sizes when comparing cRCTs with
individual-randomised RCTs [13]. One particular statis-
tical design approach may provide extra information
about the link between contamination and estimated
treatment effect sizes. Specifically, in trials that use
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treatment allocation at more than one level, a compari-
son of treatment effect estimates between cluster- and
participant-randomised sub-trials may provide some in-
formation as to the impact of contamination or the abil-
ity of cluster randomisation to prevent it.
The aims of this article were fourfold: to identify the
processes that are considered to lead to contamination
in trials of complex interventions in mental health, to
quantify typical levels of contamination, to summarise
what researchers do in order to prevent or mitigate it,
and to compare treatment effect estimates within trials
of complex interventions that used both cluster- and
individual-level treatment allocation to quantify the con-
tamination bias.
Methods
Type of review
We carried out a scoping review of trial design and con-
duct methods in RCTs of complex interventions in men-
tal health. This type of review was chosen on the basis
that our objectives were to summarise researchers’ per-
ceptions of and solutions to a trial design problem where
there is limited literature and potentially highly hetero-
geneous evidence. This was a methodology review and
did not focus on a particular patient outcome, therefore
was not eligible for registration with PROSPERO.
Eligibility criteria
All articles were screened using full texts and were
assessed using five inclusion criteria. First, the text de-
scribed a trial purporting to have used random alloca-
tion. Second, the intervention was complex, which in
this review meant it comprised multiple components. It
was not possible to assess whether these elements acted
together to provide some added benefit (as per MRC
guidance definition) so we used a general and therefore
wide definition for this. Third, the publication gave some
information about the process leading to, amount of, or
solution used to counter treatment contamination.
Fourth, the abstract and main body of the article were
written in English. And finally, the trial was related to
mental health, psychology, or psychiatry – this meant
that a minimum of one of the target population, inter-
vention, or primary outcome was directly related to one
of these fields. Many trials in these fields test unblinded
treatments where the suspicion is that they may be sub-
ject to contamination. The scoping review was limited to
these areas of medicine for this reason and because of
the apparent gap in the literature surrounding contamin-
ation in these fields.
Information sources
The search for contamination in RCTs of complex interven-
tions in mental health was done using the Ovid platform
and included the databases Medline, Embase, and PsycInfo.
Articles that were published between January 2000 and
April 2015 were searched. Results were restricted to those
articles published after 2000 because this was the year when
the first MRC framework paper on complex interventions
was first published [14]. The publication of this framework
marked the point at which the design and evaluation of
complex interventions were formalised.
Search
Randomised controlled trials were searched for using the
sensitivity-maximising 11-step process recommended by
Cochrane [15]. The search terms “contamination” and
“spillover” were included in the procedure. Synonymous
terms for complex interventions that were used included
all combinations of “multicomponent”, “psychosocial”,
and “behavioural”, with “interventions”, “treatments”, and
“training”. The search was restricted to articles that men-
tioned “mental health”, “psychology”, or “psychiatry”. All
terms were searched for in the main body of the text. The
full search procedure can be found in the supplementary
materials (see file Additional file 1).
Study selection
Duplicates were removed from the set and the remaining
articles were assessed for each of the exclusion criteria.
Any potentially relevant article that was referred to by a
paper in the results of the search and was not already in
the set was followed up by a single author (NM). If the
article was judged to have met the inclusion criteria it
was included in the set and the full text was reviewed,
also by a single author (NM). In order to assess the reli-
ability of study selection, a second reviewer (RK)
re-screened 70 articles (11%).
Data collection process
Any studies that were included in the review that featured
sub-studies that used both cluster- and individual-level
treatment allocation were reviewed as two separate
sub-trials because of the different contamination processes
and methods used to address these. Treatment effect sizes
were extracted for trials that reported effects separately
depending on the level of treatment allocation. Data from
any such studies that did not report results at the different
levels of treatment allocation were obtained from the au-
thors in order to allow the comparison.
Data items
Abstracted data included an assessment of bias, sum-
maries of trial design (e.g. study population, interven-
tion, primary outcome, unit of treatment allocation),
details about contamination (e.g. how it was thought to
take place, its quantity, steps taken to avoid it), and re-
cords of trial summaries (e.g. extent of clustering, power,
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sample size, treatment effect). In order to assess the reli-
ability of data abstraction, a second reviewer (RK)
re-extracted data from 20 articles (8%) using the same
procedure described above.
Risk of bias in individual studies
The review of trial bias included recording the “Jadad score”
(a single item measure of methodological quality of RCTs
[16]) and most of the domains of Cochrane’s classification
scheme for bias [17]. In addition to these, some other do-
mains that were pertinent to cluster randomised trials were
used. These included whether randomisation occurred after
participant consent was obtained, baseline measures were
completed before randomisation, baseline outcome mea-
surements were similar across trial arms, other clinical and
demographic characteristics were similar across arms, and
whether attrition was similar in the arms. These additional
assessments of bias were based on outcomes used in a re-
view of cRCTs [8].
Results
Reliability
At the screening stage agreement was 71%; all discrepan-
cies were discussed and subsequently resolved. Agree-
ment was 81% for all assessments of bias, and 82% for
details of contamination processes.
Summary of trials
Two hundred and thirty-four studies were identified as
meeting the eligibility criteria. This included seven trials
that were referred to by an article in the main search
and were found to meet the eligibility criteria. The re-
sults of the implementation strategy and numbers of ex-
clusions are summarised in Fig. 1. Four hundred and
fourteen articles were excluded. A list of these articles
together with reasons for exclusions can be found in the
supplementary materials (see Additional file 2).
Details of the 234 trials in the review are given in
Table 1. The table shows that the overwhelming majority
of articles described the primary analysis of an RCT, were
based in either North America or Western Europe, and
were late phase (i.e. not pilot or feasibility trials). Most tar-
get populations were adult patients and the most com-
monly targeted conditions were depression, substance
abuse, and psychosis. The two most common interven-
tions were cognitive behavioural therapy and care man-
agement; there were many small categories. The sample
size of participant randomised trials ranged from 16 to
14,910; that of cluster randomised trials ranged from 13 to
6076. A full list of references can be found in the supple-
mentary materials (see Additional file 3).
Summary of assessment of bias
Summaries of assessments of bias using the Jadad scale,
items recommended by Cochrane, and items aimed at
identifying possible bias in cluster randomised trials are
reported in Table 2. The table demonstrates the poten-
tial for bias split by the level of treatment allocation. In
general, it shows that the greatest potential for bias arose
due to lack of knowledge of allocation, incomplete
Fig. 1 Flow diagram for searching for relevant articles (articles could be excluded for more than one reason)
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outcome data, differences in attrition between trial arms,
and randomisation occurring before consent was ob-
tained and before baseline measures were completed.
More evidence for bias was found in cluster randomised
trials when assessing whether randomisation took place
after consent and after baseline measures were
completed, whether outcome assessment was blind, and
whether baseline demographic characteristics were simi-
lar between trial arms. Assessments of bias for each trial
together with the support for judgement associated with
each assessment can be found in the supplementary ma-
terials (see Additional file 3).
Table 1 Summary of characteristics of articles
Variable Level Number of articles
Type of article (n) Results of primary analysis of clinical trial 228 (97.4%)
Design / protocol of clinical trial 3 (1.3%)
Results of secondary analysis of clinical trial 3 (1.3%)
Year (n) 2000–2004 47 (20.0%)
2005–2009 85 (36.3%)
2010–2015 102 (43.6%)
Country of origin (n) USA 101 (43.2%)
UK 39 (16.7%)
Netherlands 19 (8.1%)
Canada 14 (6.0%)
Australia 11 (4.7%)
Other 50 (21.4%)
Target population (n) Adult patients 172 (73.5%)
Children / adolescent patients 45 (19.2%)
People at risk 5 (2.1%)
Workers 12 (5.1%)
Target condition (n) Depression 30 (28.6%)
Substance abuse 18 (17.1%)
Psychosis 14 (13.3%)
Neurodegeneration 13 (12.4%)
Anxiety 6 (5.7%)
Attention deficit hyperactivity disorder 5 (4.8%)
Others 19 (18.1%)
Intervention (n) Cognitive behavioural therapy / CBT skills 33 (14.1%)
Care management / interdisciplinary care 26 (11.1%)
Education 21 (9.0%)
Motivational interviewing / motivational enhancement therapy 19 (8.1%)
Other psychotherapy / counselling 16 (6.8%)
Assessment and feedback 8 (3.4%)
Parenting interventions 8 (3.4%)
Others 103 (44.0%)
Phase (n) Early (pilot and feasibility trials) 29 (12.4%)
Late 205 (87.6%)
Level of treatment allocation (n) Participant level 141 (60.3%)
Cluster level 93 (39.7%)
Sample size (median; IQR) Participant-level allocation 143 (84–261)
Cluster-level allocation 285 (158–579)
Cluster size in cRCTs (median; range) 10 (3–200)
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Processes driving contamination
There were perceived to be five main processes that led
to contamination. The first two processes, staff deliver-
ing the active intervention in the control arm (n = 82,
35%) and communication between trial arms (n = 79,
34%), were the most common. Staff delivering the active
intervention in the control arm happened either due to
a given clinician delivering both the active and control
treatments (n = 76, e.g. [18]) or due to control partici-
pants being exposed to the intervention as a conse-
quence of clinicians, who were not directly involved in
providing the treatment, treating participants in both
arms and thereby potentially learning about the active
intervention and passing this on to participants in the
control arm (n = 6, e.g. [19]). The other main contamin-
ation process was communication between individuals in
different trial arms. This could be either at the level of
the clinician (n = 20, e.g. [20]), participant (n = 57, e.g.
[21]), or both (n = 2). Communication between providers
of interventions was often a worry in environments in
which the people giving the treatment worked closely to-
gether, for example GP surgeries, hospital units, and
Table 2 Summary of assessment of bias
Variable Level Trials with individual-level
randomisation (n)
Trials with cluster
randomisation (n)
Jadad score (possible range of 0–5;
higher scores indicate lower likelihood of bias)
0 2 (1.4%) 1 (1.1%)
1 26 (18.8%) 22 (23.9%)
2 44 (31.9%) 32 (34.8%)
3 66 (47.8%) 37 (40.2%)
Allocation sequence adequately generated Low risk 75 (53.2%) 44 (47.3%)
High risk 3 (2.1%) 1 (1.1%)
Unclear 63 (44.7%) 48 (51.6%)
Allocation sequence adequately concealed Low risk 30 (21.3%) 18 (19.3%)
High risk 3 (2.1%) 1 (1.1%)
Unclear 108 (76.6%) 74 (79.6%)
Randomisation after consent obtained Low risk 116 (82.3%) 23 (24.7%)
High risk 6 (4.3%) 39 (41.9%)
Unclear / NA 19 (13.5%) 31 (33.3%)
Randomisation after baseline measures were completed Low risk 56 (39.7%) 15 (16.1%)
High risk 14 (9.9%) 41 (44.1%)
Unclear 71 (50.4) 37 (39.8%)
Baseline outcome measurements similar across trial arms Low risk 109 (77.3%) 70 (75.3%)
High risk 9 (6.4%) 11 (11.8%)
Unclear / NA 23 (16.3%) 12 (12.9%)
Baseline demographic characteristics similar across trial arms Low risk 121 (85.8%) 69 (74.2%)
High risk 3 (2.1%) 18 (19.4%)
Unclear / NA 17 (12.1%) 6 (6.5%)
Knowledge of allocation adequately concealed Low risk 0 (0%) 0 (0%)
High risk 141 (100%) 93 (100%)
Blinded outcome assessment Low risk 63 (44.7%) 29 (31.2%)
High risk 8 (5.7%) 17 (18.3%)
Unclear / NA 70 (49.6%) 47 (50.5%)
Incomplete outcome data Low risk 35 (24.8%) 22 (23.7%)
High risk 82 (58.2%) 57 (61.3)
Unclear / NA 24 (17.0%) 14 (15.1%)
Similar attrition between trial arms Low risk 85 (60.3%) 51 (54.8%)
High risk 30 (21.3%) 25 (26.9%)
Unclear / NA 26 (18.4%) 17 (18.3%)
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schools. Communication between participants was
thought to be most likely in environments in which par-
ticipants came into close contact. Examples of this in-
cluded interaction between participants who were family
members, patients in a waiting room, school children,
employees working on the same worksite, and university
students. Particular healthcare settings that were thought
to be highly likely to foster communication were ante-
natal clinics/childbirth classes, specialist clinics (e.g. sub-
stance misuse, dialysis), and wards for those admitted to
hospital.
There were perceived to be three other, more minor
processes that drove contamination. First, participants
switching clinicians (n = 4, 2%, e.g. [22]), where control
participants were treated by multiple clinicians of whom
one was trained in the active intervention. Second, par-
ticipants seeking treatment outside the trial (n = 6, 3%,
e.g. [23]). And finally, background noise, where the treat-
ment already existed to some extent within the health-
care system (n = 5, 2%, e.g. [24]). Fifty-nine articles did
not provide information about the contamination
process.
Quantity of contamination
Twenty-seven studies (12%) attempted to quantify con-
tamination. Twenty-three trials measured
individual-level contamination on a binary scale and
summaries of these quantities are given in Table 3. The
median level of contamination was 13% (IQR 5–33%).
Four trials measured contamination using a continuous
scale; three were trials of cognitive behavioural therapy and
one of cognitive analytic therapy. One created a treatment
fidelity scale and asked participants in each trial arm (be-
havioural weight control instructions, cognitive behavioural
therapy, standard counselling) about their knowledge of all
three treatments at the beginning and end of treatment
[25]. The sub-scales showed high knowledge of behavioural
weight control in the group allocated to receive behavioural
weight control instructions (mean change of 1.1 compared
to 0.5 and 0.5 in cognitive behavioural therapy and standard
arms), high knowledge of cognitive behavioural therapy in
those allocated to receive this (mean change of 1.6 com-
pared to 0.0 and 0.8 in behavioural weight control and
standard groups), and high knowledge of standard interven-
tion in the control group (mean change of 0.5 compared to
0.1 and 0.1 in behavioural weight control and cognitive be-
havioural therapy arms). This seemed to indicate receipt of
treatment in the control arm. Three RCTs showed negli-
gible evidence of treatment contamination. Of these RCTs,
one used a cognitive behavioural therapy adherence scale
(adapted CTACS) to record adherence and contamination
in the active intervention and control arms [26]. The
CTACS means were 98.0 and 98.8 in the cognitive behav-
ioural therapy and education intervention (control) arms
respectively, indicating that contamination did not occur.
Another trial found that the family-focused cognitive
behavioural therapy (FCBT; active intervention) group
scored higher than the traditional child-focused cognitive
behavioural therapy (control) group on two scales, Family
Focus (mean = 4.90 and 1.55) and Parenting Style Focus
(mean = 4.75 and 1.00) [27]. This suggested that only the
FCBT group incorporated family and parenting interven-
tions and therefore that there was little evidence of contam-
ination. The fourth trial used a scale to measure the fidelity
of the control intervention, which was good clinical care
[28]. This scale included a sub-scale for cognitive analytic
therapy and the mean for this was very low: 0.52 (SD 0.11).
This represented negligible contamination.
Solutions used to counter contamination
Methods that were used to counter contamination are
summarised in three categories: statistical design, trial
conduct, and analysis methods. Statistical design in-
cludes the use of cluster randomisation, where clusters
are chosen based on groups of participants who are
thought potentially to become contaminated by direct or
indirect links (e.g. via a shared therapist). One trial in-
flated the sample size in order to account for reduced
statistical power caused in part by contamination bias
[29]. The great majority of other methods for preventing
contamination were aspects of trial conduct, such as re-
cruitment of more clinicians to ensure that each clin-
ician only delivered one of the interventions. In terms of
analysis methods, one trial used per protocol analysis,
meaning that participants whose treatment was contami-
nated were dropped from the analysis [30]. This review
found no trials that addressed the problem of contamin-
ation by using methods from the causal inference field.
Categorisations of trial conduct solutions that were
used to avoid treatment contamination can be found in
Table 4. The sections of the table match the processes of
contamination described in the earlier section on this.
The majority of solutions used to prevent contamination
related either to preventing staff delivering the active
intervention in the control arm or preventing communi-
cation between clinicians or participants.
Four trials were concerned about contamination dur-
ing data collection and aimed to prevent this by mini-
mising interaction between researchers and participants
[31–34]. Another temporally separated the control and
active treatments with data collection following each.
This meant that treatment could only influence data
from active intervention participants [35].
Trials using both cluster- and participant-level treatment
allocation
The results of the review included four trials that used
both participant- and cluster-level treatment allocation
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Table 3 Quantifying treatment contamination where treatment receipt was defined as binary
Reference Control treatment Active intervention Measure of contamination Contamination (control
participants receiving
intervention)
Aveyard et al.
[40]
Basic behavioural
support for smoking
cessation
Behavioural support for smoking cessation Nurse visit (1st extra);
Telephone call;
Nurse visit (2nd extra)
12/469 (3%)
12/469 (3%)
5/469 (1%)
Barton et al.
[41]
No treatment Mammography education (pamphlet and
videotape) focusing on anxiety
Patient recall of:
Pamphlet;
Videotape
9%
1%
Bernstein et
al. [42]
No treatment Cognitive behavioural therapy Service Questionnaire of anxiety
treatment
0/24 (0%)
Borland et al.
[43]
Minimal information Behavioural support Patients reporting use of
extensive behavioural support
45/378 (12%)
Clarkson et al.
[36]
Routine care Self-efficacy education Participants reporting use of
electric toothbrush
9/113 (8%)p
9/180 (5%)c
Courneya et
al. [44]
Group psychotherapy Group psychotherapy and exercise
programme
Patient-reported exercise 10/45 (22%)
Dilley et al.
[45]
Usual care Cognitive counselling Patient-reported receipt of
counselling
45/158 (29%)
Forchuk et al.
[46]
Usual care Transitional discharge from hospital Patient-reported receipt of peer
support and staff contact
27%
Heirich &
Sieck [47]
Health education Proactive follow-up counselling Patients requesting personal
counselling
56%
Johnson et al.
[20]
Usual treatment Clinical training in dual diagnosis
of psychosis and substance misuse
Patients not taken on by trained
case manager
19/105 (18%)
Khumalo-
Sakutukwa et
al. [48]
Standard HIV voluntary
counselling and testing
HIV counselling, testing and
self-management
Participants seeking out
treatment from intervention
centres
1%
Lamers et al.
[49]
Usual care Nurse-led minimal
psychological intervention (MPI)
Patients who reported
knowledge of MPI
9/178 (5%)
Lee & Gayp
[37]
Attention control Sleep hygiene package Patient-reported use of:
Bassinet;
White noise device;
Low lighting
33/46 (72%)p
47/75 (62%)c
11/75 (14%)c
27/75 (36%)c
Merritt et al.
[50]
No intervention Postcards with information
about depression
Patients reporting having seen
the postcards
7/78 (1%)
Moadel et al.
[51]
Standard care Smoking cessation group support
and encouragement
Patients reporting discussion of
active intervention patients;
Patients reporting familiarity with
program’s strategies
6%
17%
Mohr et al.
[52]
Treatment as usual Cognitive behavioural therapy Patients who had contact with
non-study therapist
18/44 (41%)
Phillips et al.
[53]
Routine public health
practice
Community engagement in healthy
eating
Participants reporting
participation in intervention
programme
1%
Saitz et al.
[54]
Usual care Chronic care management (multidisciplinary
care coordination; motivational therapy;
counselling)
Patients who received a session
of motivational enhancement
therapy
9/281 (3%)
Shemilt et al.
[55]
No funding for breakfast
club
Funding for school-based breakfast club School pupils with school
breakfast club
77%
Stewart-
Brown et al.
[56]
No intervention Incredible Years (parenting techniques)
training
Participants attending
community-based parenting
programme
4/44 (9%)
Waghorn et
al. [57]
Enhanced routine
mental health case
management
Supported employment and specialist illness
management
Patients opting to transfer to
intervention after 6 months
28/102 (27%)
Walpole et al.
[58]
Social skills training Motivational interviewing (MI) Patients whose treatment was MI
adherent
37%
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[36–39]. Treatment effect estimates and confidence in-
tervals for these trials are shown in Fig. 2. The figure
shows treatment effects arranged such that greater bene-
fit (or less harm) of treatment is represented by a greater
number on the horizontal axis. The figure enables the
comparison of the absolute size of treatment effect be-
tween participant- and cluster-level allocation to assess
the impact of contamination on effect size estimation.
Of the 21 outcomes investigated, just under half of out-
comes showed a difference in the anticipated direction,
i.e. smaller estimated absolute effect sizes under
participant-level random allocation. In particular, an at-
tenuated treatment effect (lesser distance from the null
line in Fig. 2) was found under participant-level
Table 3 Quantifying treatment contamination where treatment receipt was defined as binary (Continued)
Reference Control treatment Active intervention Measure of contamination Contamination (control
participants receiving
intervention)
Wells et al.
[59]
Usual care Quality improvement therapy (CBT) and
medications (assessment and education)
Receipt of speciality counselling
within 6 months
13%
pUsing participant-level treatment allocation
cUsing cluster-level treatment allocation
Table 4 Trial conduct solutions to treatment contamination
Process driving contamination Trial conduct solution Number
of papers
Clinicians deliver both active and control
treatments
Recruiting groups of clinicians, each one of which is responsible for a single treatment 16
Monitoring contamination using supervision/therapy session recordings 10
Formalising differences between interventions, e.g. using structured manual during
therapist training
6
Asking clinicians not to use intervention content when treating those in control arm 3
Providing active intervention within the research project rather than health service 1
Using a script for contact with control participants during treatment 1
Clinicians not involved in active intervention
treating participants in both trial arms
Blinding usual care clinicians 4
Confining intervention to provision by specialist clinicians 2
Communication between clinicians in different
trial arms
Asking clinicians not to share details of the intervention with each other 5
Communication between participants in different
trial arms
Holding treatment sessions at different times / in different locations 13
Staggering the scheduling of data collection appointments / reducing waiting time so
that participants do not meet in waiting room
3
Allocating separate therapists / modes of delivery for individual and group therapies
when usual group therapy was shared by participants in both arms
2
Asking participants not to share contents of intervention with others 2
Excluding potential participants who know someone else attending screening 2
Holding separate sessions of existing group treatments for participants in separate trial
arms in order to prevent contact
1
Restricting the release of intervention materials in order to reduce the chance of their
being shared with control participants
1
Recruiting participants in blocks and providing one treatment at a time, with no new
participants recruited during the final week of each period in order to maintain
separation between trial arms
1
Participants switching clinicians and therefore
trial arms
Preventing referrals for add-on care by clinicians who are members of study team 1
Avoiding transfer of participants between clinicians 1
Participants seeking treatment outside the trial Informing participants only about the treatment they were allocated to receive (Zelen’s
design)
8
Promising the intervention to control participants at the end of follow-up 2
Active treatment is available to some extent
within the healthcare system
Making intervention distinct from usual care by adapting one or other 2
Establishing common treatment for all participants 1
Excluding institutions that already offer some aspect of the intervention 1
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allocation in eight out of 21 outcomes with a tie in one
outcome.
Discussion
The review identified 234 articles that described either
the processes driving treatment contamination, its quan-
tity, or steps that researchers took to prevent or alleviate
the problem in trials of complex interventions in mental
health. The principal processes leading to contamination
were found to be clinicians being required to treat par-
ticipants in both treatment and control conditions and
communication among clinicians or participants in
different trial arms. Typically, around one in eight par-
ticipants in the control arm of a trial were assessed as
having received the active intervention. The most com-
mon steps that researchers took to prevent or mitigate
contamination were the use of cluster randomisation,
organising for each clinician to provide only one type of
treatment, monitoring treatment receipt, spatially or
temporally separating trial arms, and informing partici-
pants about only the treatment that they were allocated
to receive. There was little evidence of a difference in
the magnitude of treatment effects within trials that used
both cluster- and participant-level treatment allocation.
Fig. 2 Forest plots for four trials that used both individual- and cluster-level randomisation; (P) = primary outcome. a) Clarkson et al. (2009) [36].
Choice of primary outcomes is based on sample size calculation; estimates are adjusted for baseline measures. Larger (more positive) treatment
effects indicate benefit. b) Lee & Gay (2011) [37]. Estimates were standardised and calculated from summaries of means and SDs (mothers’ scores
only). Larger (more positive) treatment effects indicate benefit. c) Marshall et al. (2004) [38]. Estimates used same adjustments as in the trial publication.
Larger (more positive) treatment effects indicate benefit. d) Richards et al. (2008) [39]. Estimates were standardised and calculated from summaries of
means and SDs. Larger (more positive) treatment effects indicate benefit
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The classification of two main processes and three
more minor types of contamination was based on the
processes that researchers and clinicians described in
such trials. The main trial conduct steps that researchers
took to minimise contamination were in line with the
processes that were found to be driving it. Many
researchers attempted to design against contamination
by carefully controlling the treatment’s delivery. These
processes were often anticipated and then prevented or
attenuated by the designers of the trials. There were no
examples of researchers first having evaluated in detail
treatment receipt within the control arm. The processes
described here therefore partly represent researchers’ ex-
pectations and not entirely clinician or participant
behaviour.
The small number of trials that measured and re-
ported treatment receipt in the control arm found it to
be affecting a minority of the control participants. The
distribution of this was similar to the quantity found
previously in other areas of medicine such as educa-
tional interventions [1], breast cancer screening [4], and
cancer trials using Zelen’s design [5]. Thus while there is
a lot of concern about contamination it is not clear that
this problem is indeed widespread. The extent of the
problem may be related to the complexity, intensity, and
nature of the intervention.
Researchers often used cluster randomisation to pre-
vent treatment contamination, amongst other reasons.
While cRCTs can avoid contamination bias they are at
risk of other biases. Our set of articles included 93 clus-
ter randomised trials. Assessments of bias suggested that
cRCTs were more likely to be affected by bias when con-
sidering whether randomisation took place after consent
was obtained and after baseline measures were com-
pleted, whether outcome assessment was blind, and
whether demographic characteristics were similar be-
tween trial arms. This was consistent with an earlier re-
view of cRCTs that were published in three prominent
medical journals which found evidence of recruitment
bias [8].
The small number of trials that allocated treatment at
both cluster and participant levels did not find any evidence
for differences in effect size estimates. The lack of evidence
for a link between the level of randomisation and treatment
effect size suggested that either the employment of cluster
randomisation did not prevent contamination, the antici-
pated contamination was overstated, or that the use of clus-
ter randomisation led to a similar degree of bias as that
caused by contamination in the participant-randomised tri-
als. Overall, the finding was consistent with those of a
review of trials of enhanced care in depression [12], and of
educational interventions [1]. Similarly to previous reviews,
there was considerable heterogeneity between trials identi-
fied in this study that used both cluster- and
participant-level randomisation. However, the variability
here is between trials and not within them because ran-
domisation implies that the sub-trials were balanced for
every variable except the level at which treatment allocation
took place. It is possible that the impacts of contamination
and cluster randomisation on bias are dependent on the
disease or type of intervention. In order to draw substantive
conclusions about the effect of treatment allocation level
on contamination, a systematic review of this particular
trial design is needed.
Conclusions
This is the most comprehensive review of contamination
in mental health trials to date. It is the first to identify the
processes leading to contamination and the measures that
researchers take in order to minimise the problem. The
main limitation is that the trials were heterogeneous in
that they represented a large range of illnesses and inter-
ventions. With regard to the causes of contamination, it is
an assumption that the processes described by authors
were the drivers of contamination. Another limitation is
the time interval between the literature search and publi-
cation of this review. It is possible that the problems, solu-
tions and reporting of contamination have evolved since
the search took place.
The results of this review suggest that treatment con-
tamination is perceived to be a significant problem in tri-
als of complex interventions in mental health. However,
the trials that measured and reported it suggest that the
phenomenon is often modest (with a large range). The
reporting of it is infrequent and almost certainly not as
commonplace as that of treatment non-compliance. This
implies a need for greater measurement and reporting of
treatment receipt in the control arm of trials in this field.
The findings also show that there are many steps that re-
searchers can take to minimise contamination without
resorting to the use of cluster randomisation. In addition,
we found that modern causal analysis methods, including
the techniques developed particularly for contamination
adjustment [9, 10], are yet to be utilised to deal with con-
tamination bias at the analysis stage. This is likely to be in
part a reflection of the infrequency of measurement of
treatment receipt for all participants in the control trial
arm.
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